dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Jun 25, 2015 20:14:17 GMT -5
P RESS RELEASE
NOVAVAX APPOINTS GAIL BOUDREAUX TO BOARD
GAITHERSBURG, Md., June 18, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Gail K. Boudreaux to its Board of Directors.
“We are delighted to welcome Gail to Novavax’ Board,” said Stanley C. Erck, President and CEO of Novavax. “Her outstanding leadership and business experience will be important to our continued growth and success. Gail’s insight on health payors will be particularly important as we continue to move towards commercialization of our vaccines.”
Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience includes more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is currently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.
“I am very happy to be joining Novavax at such an exciting time,” said Ms. Boudreaux. “I look forward to helping the company achieve its goal to develop and deliver safe and effective vaccines to improve global heath.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact:
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations |
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Jun 25, 2015 20:16:09 GMT -5
PRESS RELEASE
NOVAVAX RECOGNIZED BY WASHINGTON POST AS TOP WORKPLACE GAITHERSBURG, Md., June 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that, for the second consecutive year, it has been recognized as a Top Workplace for 2015.
“This recognition is a testament to the passion and dedication of our 350 SuperNovas,” said Stanley C. Erck, President and CEO. “Our employees exemplify the excellence and commitment necessary to make an impact on global health. I come to work every day excited to work with each and every one of them.”
The Washington Post Top Workplaces are determined solely on employee feedback via an employee survey conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement.
Jill Hoyt, Vice President, Human Resources, said, “It is an honor to receive this recognition for the second year in a row. This award underscores Novavax’ commitment to creating a culture where our employees are a key part of innovative solutions, cutting-edge technology and shared success.”
The Washington Post publishes the complete list of Top Workplaces on June 21st. For more information about the Top Workplaces lists, please visit www.topworkplaces.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com. |
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Jul 30, 2015 12:11:51 GMT -5
|
|
dothedd
Senior Member
Joined: Dec 27, 2010 20:43:28 GMT -5
Posts: 2,683
|
Post by dothedd on Oct 27, 2015 14:50:01 GMT -5
RSV CLINICAL TRIALS
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women
Status: Ongoing, not recruiting Identifier: NCT0224776
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Pediatrics
Status: Ongoing, not recruiting Identifier: NCT02296463
Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Seniors
Status: Ongoing, not recruiting Identifier: NCT02266628
RSV F Dose-Ranging Study in Women
Status: Completed Identifier: NCT01960686
RSV-F Vaccine Dose Ranging Study in Young Women
Status: Completed Identifier: NCT01704365
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
Status: Completed Identifier: NCT01290419
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
Status: Completed
novavax.com/page/12/clinical-trials
|
|
